Günümüzde, FOLFOX (5-fluorourasil, leucoverin ve oxaliplatin) ileri evre veya metastatik
gastrointestinal sistem tümörlerinde ilk sýrada kullanýlan kemoterapötik rejimdir. Bu rejimin
hematolojik, gastrointestinal ve sensörinöral sistem ile ilgili yan etkileri bilinmesine karþýn pulmoner
toksisitesi sýnýrlý sayýda olgu bildirimleri düzeyindedir. Hýzla ilerleyerek mortal seyredebileceðinden
akciðer toksisitesinin erken farkýndalýðý ve tedavisi önemlidir. Bu yazýda, metastatik özofagus kanseri
nedeniyle kullanýlan FOLFOX tedavisine sekonder geliþen interstisyel akciðer hastalýðý olgusu nadir
olmasý nedeniyle sunulmuþtur.
To date, 5-fluorourasil, leucovorin, and oxaliplatin (FOLFOX) continues to be used as a first-line treatment for advanced or metastatic gastrointestinal system tumors. Though associated hematological, gastrointestinal, and neurosensory toxicities are widely known, pulmonary toxicity has solely been described in case reports. Early diagnosis and treatment is extremely important, since the toxicity may lead to rapid deterioration and mortality. Presently described is the case of a female patient with interstitial lung disease secondary to undergoing a FOLFOX regimen for metastatic esophagus cancer.
Keywords: drug toxicity, interstitial lung disease, oxaliplatin